Company
Recordati Rare
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
8 still marketed
Novel approvals
8
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Isturisa new use OrphanJul 3, 2025
- Isturisa new use OrphanApr 15, 2025
- Carbaglu new use Priority reviewOrphanJan 22, 2021
- Carbaglu new use Priority reviewOrphanJan 22, 2021
- Cystadrops approved Aug 19, 2020
- Isturisa approved NovelOrphanMar 6, 2020
- Signifor new use Jan 15, 2020
- Cosmegen new use Aug 15, 2018
- Cosmegen new use Aug 15, 2018
- Signifor Lar Kit new use OrphanJun 29, 2018
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (8)
Newest FDA action first.
- Isturisa Osilodrostat Phosphate · 2020
- Chemet Succimer · 1991
- Signifor Lar Kit Pasireotide Pamoate · 2014
- Signifor Pasireotide Diaspartate · 2012
- Carbaglu Carglumic Acid · 2010
- Neoprofen Ibuprofen Lysine · 2006
- Cystadrops Cysteamine Hydrochloride · 2020
- Cystadane Betaine · 1996
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.